Louis Ferrari
Ferrari was promoted in preparation for the launch of KRYSTEXXA, the first FDA approved therapy for the treatment of refractory chronic gout.
He will work with the firm's new interim CEO David Norton todrive the productivity of commercial operations.
Norton was drafted in to replace John Johnson, who resigned to become the new CEO of Dendreon Corporation.